{"id":551024,"date":"2021-07-02T17:08:01","date_gmt":"2021-07-02T17:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551024"},"modified":"2021-07-02T17:08:01","modified_gmt":"2021-07-02T17:08:01","slug":"chronic-wounds-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-wounds-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_551024.html","title":{"rendered":"Chronic Wounds Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625203573.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Wounds Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625203573.png\" alt=\"Chronic Wounds Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cChronic Wounds Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the Chronic Wounds pipeline landscapes. It comprises Chronic Wounds pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chronic Wounds therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chronic Wounds pipeline products.     <\/p>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&rsquo;s <\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-wounds-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span data-mce-mark=\"1\">&ldquo;<\/span><strong><span data-mce-mark=\"1\">Chronic Wounds Pipeline Insight<\/span><\/strong><span data-mce-mark=\"1\">&rdquo;<\/span><\/a><span data-mce-mark=\"1\"> report provides comprehensive insights about key companies<\/span><span data-mce-mark=\"1\">&nbsp;and pipeline drugs in the Chronic Wounds pipeline landscapes. It comprises Chronic Wounds pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chronic Wounds therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chronic Wounds pipeline products.&nbsp; &nbsp; &nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Some of the key takeaways of the <\/span><span data-mce-mark=\"1\">Chronic Wounds Pipeline Report<\/span><span data-mce-mark=\"1\">:<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as <\/span><span data-mce-mark=\"1\">Anterogen, ViroMed BioPharma, Novalead Pharma, Oneness Biotech, MediWound, Tissue Tech\/Amniox Medical, Charsire Biotechnology, Energenesis Biomedical,<\/span><span data-mce-mark=\"1\"> etc., are developing therapies for the treatment of Chronic Wounds.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Emerging therapies such as <\/span><span data-mce-mark=\"1\">ALLO-ASC-DFU, Engensis, Galnobax, ON101, EscharEx, TTAX01, CSTC1, ENERGI-F703,<\/span><span data-mce-mark=\"1\">are expected to have a significant impact on the <\/span><span data-mce-mark=\"1\">&nbsp;Chronic Wounds <\/span><span data-mce-mark=\"1\">market in the coming years.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Galnobax, <\/span><span data-mce-mark=\"1\">by Novalead Pharma, has completed a global Phase I\/II clinical trial in DFU successfully meeting both primary and secondary endpoints for both safety and efficacy. The company is investigating it in the Phase III clinical trial.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Get an overview of pipeline landscape @ <\/span><span data-mce-mark=\"1\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-wounds-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Chronic Wounds Clinical Trials Analysis<\/a>&nbsp;<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">A chronic wound is a wound that does not heal in an orderly set of stages and in a predictable amount of time the way most wounds do; wounds that do not heal within three months are often considered chronic.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-wounds-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span data-mce-mark=\"1\">Chronic Wounds Emerging Drugs<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Galnobax by Novalead Pharma<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Galnobax, by Novalead Pharma, is a topical gel of Esmolol hydrochloride for the treatment of hard to heal diabetic foot ulcers. It is a repurposed generic drug molecule, which has completed a global Phase I\/II clinical trial in DFU successfully meeting both primary and secondary endpoints for both safety and efficacy.<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Engensis by ViroMed BioPharma<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Engensis(VM202) is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms needed for optimal therapeutic benefits.<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>ON101 by Oneness Biotech<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Oneness Biotech is also coming up with its new botanical drug ointment, ON101. Clinical studies demonstrated that ON101 has significant therapeutic effects on wound healing and could reduce scar formation.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>TTAX01 by Tissue Tech<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>One Pharma Company named Tissue Tech, which is developing a product TTAX01 for the management of venous leg ulcers and non healing wounds.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>EscharEx by MediWound&nbsp;<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Another topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds is being developed by MediWound, named EscharEx. It is a mixture of proteolytic enzymes for the management of debridement in chronic and other hard-to-heal wounds<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><span data-mce-mark=\"1\">Scope of <\/span><span data-mce-mark=\"1\">Chronic Wounds Pipeline Drug Insight <\/span><span data-mce-mark=\"1\">&nbsp; &nbsp;<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Coverage: <\/span><span data-mce-mark=\"1\">Global&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Major Players:<\/span><span data-mce-mark=\"1\"> Anterogen, ViroMed BioPharma, Novalead Pharma, Oneness Biotech, MediWound, Tissue Tech\/Amniox Medical, Charsire Biotechnology, Energenesis Biomedical, and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Pipeline Therapies:<\/span><span data-mce-mark=\"1\">&nbsp; ALLO-ASC-DFU, Engensis, Galnobax, ON101, EscharEx, TTAX01, CSTC1, ENERGI-F703, and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><span data-mce-mark=\"1\">Table of Contents:<\/span><\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">1<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Report Introduction<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">2<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Executive Summary<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">3<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Overview<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">4<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds- Analytical Perspective In-depth Commercial Assessment<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">5<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Pipeline Therapeutics<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">6<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Late Stage Products (Phase II\/III)<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">7<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Mid Stage Products (Phase II)<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">8<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Early Stage Products (Phase I)<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">9<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Preclinical Stage Products<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">10<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Therapeutics Assessment<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">11<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Inactive Products<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">12<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">13<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Key Companies<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">14<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Key Products<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">15<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Unmet Needs<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">16&nbsp;<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Market Drivers and Barriers<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">17<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Future Perspectives and Conclusion<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">18<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Chronic Wounds Analyst Views<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">19<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">Appendix<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">20<\/span><\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong><span data-mce-mark=\"1\">About DelveInsight<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-wounds-market-report?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Chronic Wounds Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s Chronic Wounds &#8211; Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Chronic Wounds, historical and forecasted epidemiology as well as the Chronic Wounds market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-wounds-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Chronic Wounds Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s Chronic Wounds &#8211; Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Chronic Wounds epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">About <\/span><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers <\/span><span>Healthcare Consulting Services<\/span><span>, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-wounds-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-wounds-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cChronic Wounds Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the Chronic Wounds pipeline landscapes. It comprises Chronic Wounds pipeline drug profiles, including clinical and non-clinical stage products. It also &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-wounds-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_551024.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-551024","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=551024"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551024\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=551024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=551024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=551024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}